Depressive Disorder, Major Clinical Trial
Official title:
The Effects of Mood and Tryptophan Depletion on the Neural Correlates of Affective Shifting in Mood Disorders
Verified date | January 15, 2014 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will investigate how the brain process emotions in healthy people and in patients
who have major depression in order to better understand the causes of depression. It will
examine what happens in the brain when a person responds to words related to different
emotions while the brain's ability to manufacture a chemical called serotonin is reduced.
Serotonin regulates functions such as emotion, anxiety and sleep, and stress hormones such as
cortisol. In this study, participants' serotonin levels are reduced by depleting tryptophan,
an amino acid that is the main building block for serotonin.
Healthy volunteers and patients with major depression that has been in remission for at least
3 months may be eligible for this study. Candidates must be between 18 and 50 years of age
and right-handed. They are interviewed about their medical and psychiatric history, current
emotional state and sleep pattern, and family history of psychiatric disorders. Screening
also includes psychiatric interviews and rating scales, neuropsychological tests, physical
examination, electrocardiogram (EKG), and blood, urine, and saliva tests. Women have their
menstrual phase determined by a blood test and home urine ovulation test kit.
The study involves two clinic visits in which participants undergo tryptophan depletion and
magnetic resonance imaging (MRI). Subjects arrive at the NIH Clinical Center in the morning
after fasting overnight. They fill out questionnaires have a blood sample drawn, and then
take 74 capsules that contain a mixture of amino acids found in the diet. At one visit they
are given capsules that contain a balanced mixture of amino acids one would normally eat in a
day; at the other visit, some of the capsules contain lactose instead of tryptophan, causing
tryptophan depletion. At 2 p.m. participants fill out the same questionnaires they completed
at the beginning of the day and have another blood sample drawn. Then they do a computerized
test in the MRI scanner. MRI uses a magnet and radio waves to obtain pictures of the brain.
For the test, subjects lie on a narrow bed that slides into the cylindrical MRI scanner. They
are asked to press a button in response to words associated with different emotions that
appear on a screen. Arterial spin labeling - a test that uses magnetism to measure blood flow
in different areas of the brain-is also done during the procedure. After the scan, subjects
eat a meal and then return home.
DNA from the participants' blood samples is also examined to try to better understand the
genetic causes of depression. Some of the white cells from the samples may also be grown in
the laboratory so that additional studies can be done later.
...
Status | Completed |
Enrollment | 95 |
Est. completion date | January 15, 2014 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
- INCLUSION CRITERIA: Healthy Volunteers Right-handed subjects (ages 18-50) will be selected who have not met criteria for any major psychiatric disorder, have no known first-degree relatives with mood disorders, and have a current score on the Hamilton Depression Rating Scale (HDRS; 17 item) in the not depressed range ( 7). Control subjects will be matched to depressed subjects and their relatives for age, gender, and education. MDD Samples Right-handed subjects (ages 18-50) will be selected with a past history of MDD by DSM-IV criteria. Healthy Relatives Healthy, right-handed, first-degree relatives of patients with MDD will be recruited. EXCLUSION CRITERIA: Subjects must not have taken antidepressant drugs for at least 3 months (4 months for fluoxetine) prior to the fMRI studies or other medications likely to alter monoamine neurochemistry or cerebrovascular and cardiovascular function for at least 3 weeks prior to imaging. However, effective medications will not be discontinued for the purposes of this study. Subjects will also be excluded if they have: 1. Psychosis 2. Medical or neurological illnesses likely to affect physiology or anatomy, i.e. hypertension, cardiovascular disorders 3. A history of drug (including benzodiazepines (BZD)) abuse within 1 year or a lifetime history of drug dependence (DSM IV criteria) 4. A history of alcohol abuse within 1 year or a lifetime history of alcohol dependence (DSM IV criteria) 5. Current pregnancy (as documented by pregnancy testing at screening or at days of the challenge studies) 6. Current breast feeding 7. Are smokers 8. Serious suicidal ideation or behavior. In this study, there is a small risk of transient depressive symptoms occurring after ingesting the amino acid mixture. Therefore, if volunteers manifest evidence of serious suicidal ideation or behavior, they will be excluded from participating. Criteria for meeting suicidal ideation include but are not limited to: 1) thoughts of suicide within the past 3 months which are accompanied by intent to harm oneself, serious consideration of means or plan to attempt suicide, evidence of arranging for a suicide attempt (e.g. giving away prized possessions or updating a will), or clear desire to commit suicide, 2) severity of past suicide events, if applicable or 3) a current plan for harming themselves. All assessments will be conducted by an experienced, NIMH credentialed health professional, such as a psychiatrist or psychiatric nurse who will use their expert knowledge and experiences in determining the authenticity of a participant s information and handle the situation accordingly. 9. General MRI exclusion criteria Subjects must exhibit no or only moderate alcohol use. Subjects with current or previous regular use (greater than 4 weeks) of BZDs and excessive use of alcohol (greater than 8 ounces/day for men and greater than 6 ounces/day for women) in the past or present are ineligible for participation, as such drug use may confound the results. Smokers (regular use within the last 3 months) are ineligible because of the evidence for interactions between nicotine and depression, and the possibility of withdrawal symptoms that may affect behavioral and neural responses to TD. Subjects beyond age 50 are excluded to address the biological heterogeneity encompassed by the MDD criteria, since depressives whose age-at-onset is later than 50 have a far greater likelihood of having MRI correlates of cerebrovascular disease than age-matched healthy controls or age-matched early-onset depressives. Subjects whose first major depressive episodes arose temporally after other medical or psychiatric conditions will also be excluded, since their functional imaging results generally differ from those reported in primary MDD. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997 Apr 24;386(6627):824-7. — View Citation
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996 Nov 29;274(5292):1527-31. — View Citation
Moreno FA, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J, Delgado PL. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol Psychiatry. 2002;7(2):213-6. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT05988333 -
Psychoeducational Intervention for Families With a Member Affected by Major Depression
|
N/A | |
Completed |
NCT02919501 -
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
|
Phase 2 | |
Completed |
NCT00976560 -
Clinical Study to Test a New Drug to Treat Major Depression
|
Phase 2 | |
Recruiting |
NCT05518149 -
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Not yet recruiting |
NCT06303076 -
Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial
|
Phase 4 | |
Not yet recruiting |
NCT05901571 -
Acupuncture and Escitalopram for Treating Major Depression Clinical Study
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Suspended |
NCT02546024 -
Predictors of Treatment Response in Late-onset Major Depressive Disorder
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01583400 -
Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial
|
N/A | |
Completed |
NCT01152996 -
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
|
Phase 3 | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00366652 -
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
|
Phase 3 | |
Completed |
NCT00384033 -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT00369343 -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 | |
Completed |
NCT00149643 -
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
|
Phase 2 |